HTRA3 and cancer: In summary, HtrA3 mAbs developed in this study will enable thorough investigations into the mechanisms of isoform-specific actions of HtrA3 in ovary development, placental development and cancer progression, and provide a means to characterise the effects of dysregulation of HtrA3 in these processes.